Tamoxifen and its active metabolite inhibit growth of estrogen receptor-negative MDA-MB-435 cells

Biochemical Pharmacology

Volumn 49, Issue 3, 1995, Pages 351-358

  Charlier, Corinne ^a   Chariot, Alain ^a   Antoine, Nadine ^a   Merville, Marie Paule ^a   Gielen, Jacques ^a   Castronovo, Vincent ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

breast cancer; estrogen receptor negative; proliferation; tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; DRUG METABOLITE; ESTRADIOL; ESTROGEN RECEPTOR; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; TUMOR GROWTH;

BREAST NEOPLASMS; CELL DIVISION; ESTROGENS; HUMAN; RECEPTORS, ESTROGEN; RNA, MESSENGER; SUPPORT, NON-U.S. GOV'T; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0028831806     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(94)00492-5     Document Type: Article

References (38)

1. National Cancer for Health Statistics: Vital Statistics of the United States, 10/87, Vol. 2, Mortality
2. Breast cancer (I)
3. Breast cancer (II)
4. Breast cancer (III)
5. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen receptor-positive tumors
6. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
7. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
8. New perspective on cancer of the contralateral breast: A marker for assessing tamoxifen as a preventive agent
9. Evaluation of tamoxifen dose in advanced breast cancer: A progress report
10. Tamoxifen and metabolites in MCF7 cells: Correlation between binding to estrogen receptor and inhibition of cell growth
11. Growth factor involvement in the multihormonal regulation of MCF7 breast cancer cell growth in soft agar
12. Evidence that transforming growth factor β is a hormonally regulated negative growth factor in human breast cancer cells
13. Tamoxifen inhibits lipid peroxidation in cardiac microsomes
14. Accumulation of a non-binding form of estrogen receptor in MCF7 cells under hydroxytamoxifen treatment
15. A simple, rapid, and sensitive DNA assay procedure
16. Comparison of monoclonal antibodies and tritiated ligands for estrogen receptor assays in 241 breast cancer cytosols.
17. Steroid hormone receptors in breast cancer treatment strategy
18. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
19. Altered levels of laminin receptor mRNA in various human carcinoma cells that have different abilities to bind laminin.
20. Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast-cancer cells
21. Expression of a constitutively active estrogen receptor variant in the estrogen receptor negative BT20 human breast cancer cell line
22. Molecular structure of the human cytoplasmic β-actin gene: Interspecies homology of sequences in the introns?
23. Up-regulation of estrogen receptors by nonsteroidal antiestrogens in human breast cancer
24. Isolation and characterization of a tamoxifen-resistant cell line derived from MCF7 human breast cancer cells
25. 1 phase
26. Differential effects of tamoxifen and analogs with nonbasic side chains on cell proliferation in vitro
27. Tamoxifen inhibits growth of oestrogen receptor-negative A549 cells
28. Antiestrogen-binding sites distinct from the estrogen receptor: Subcellular localization, ligand specificity, and distribution in tissues of the rat
29. Physicochemical and genetic evidence for specific antiestrogen binding sites
30. The complexity of anti-estrogen responses
31. Antisteroidal and anti-growth factor activities of antiestrogens
32. Antiestrogen action in breast cancer cells: Modulation of proliferation and protein synthesis and interaction with estrogen receptors and additional antiestrogen binding sites
33. Displacement by tamoxifen of the estradiol-estrogen receptor binding: A functional assay for breast cancer studies
34. Resistance to tamoxifen with persisting sensitivity to estrogen: Possible mediation by excessive antiestrogen binding site activity
35. Role of specific interactions between protein kinase C and triphenylethylenes in inhibition of the enzyme
36. 2+ exchange of brain cortex membranes
37. Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; Correlations with cytotoxicity
38. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment